Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies that degrade disease-causing proteins. Its proprietary technology, called proteolysis targeting chimeras (PROTAC), harnesses the body's natural protein disposal system to target and remove harmful proteins. The company's pipeline includes several investigational drugs: vepdegestrant for ER+/HER2- breast cancer; bavdegalutamide (ARV-110) and luxdegalutamide (ARV-766) for metastatic castration-resistant prostate cancer; ARV-102 for neurodegenerative diseases like Parkinson's; ARV-806 for cancers with the G12D mutation; ARV-393 for relapsed/refractory non-Hodgkin lymphoma; and ARV-027 for polyglutamine-expanded androgen receptor in skeletal muscle. Arvinas also has collaborations with Pfizer, Genentech, Roche, Carrick Therapeutics, and Bayer.

Arvinas, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ARVN. The stock trades in US Dollars (USD), as the company is based in the United States. Being listed on a major US exchange provides liquidity and access to a broad investor base.

Arvinas operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing innovative therapies for serious diseases, including various cancers and neurodegenerative disorders. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight.

Arvinas is headquartered in New Haven, Connecticut, United States. The company was founded in 2013 and primarily serves the US market, though its collaborations with global pharmaceutical companies like Pfizer, Roche, and Bayer indicate a broader international reach. Its therapies target diseases that affect patients worldwide, such as breast cancer, prostate cancer, and Parkinson's disease.

As a clinical-stage biotechnology company, Arvinas does not yet have approved products on the market, so it currently generates revenue primarily through collaboration agreements with larger pharmaceutical companies. These collaborations include partnerships with Pfizer, Genentech (a Roche subsidiary), F. Hoffman-La Roche, Carrick Therapeutics, and Bayer. Under these deals, Arvinas typically receives upfront payments, milestone payments, and royalties on future product sales. The company's long-term business model aims to develop and commercialize its own PROTAC-based therapies, targeting protein degradation for diseases with high unmet medical need.